Study #2020-0638
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients with Bcell Malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
Zanubrutinib, Tislelizumab
Description
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
B-cell Malignancies
Study phase:
Phase III
Physician name:
Michael Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-866-599-0508
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.